Speclipse develops a laser spectroscopic technique combined with AI and deep learning to analyze blood spectroscopic data for medical diagnosis. The technology, originally used for tissue diagnostics, has been adapted to blood analysis to detect small variances across multiple blood biomarkers simultaneously. The company applies AI to process large volumes of spectroscopic data and aims to enable early diagnosis of gastric cancer and Alzheimer’s disease. Speclipse is led by Sung Hyun Pyun and is based in Seoul, South Korea. It plans to use newly raised capital to accelerate growth, expand operations, and broaden its business reach. The article does not disclose operating metrics beyond the recent financing.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2021